Kornimate/medical-research-clean huggingface dataset:
treatment of residual hypermetropic refraction on young patients after lasik using human fresh corneal lenticule implantation with relex smile surgery

Conditions: Refractive Errors

Summary: lasik (laser-assisted in situ keratomileusis) is a type of refractive surgery for correction of myopia, hyperopia and astigmatism. yet approximately 30% of operated patients have symptoms like glare, halos, dry eyes and especially residual hypermetrop refractive errors. residual hypermetrop refractive errors are difficult to treat surgically, the current treatment is refractive lens implantation - risks are similar to those of cataract surgery (endophthalmitis, loss of accommodation, etc.)

the main problem at young patients post - lasik after one year is residual refractive errors. the method used in eye hospital is treatment with implantation of human fresh corneal lenticule (min. -1.50d) taken from myopic patients in post - lasik patients with residual refractive error (min. +1.0d). 1. the flap of lasik is lifted, cleaned and then the lenticule is gently inserted. the fresh myopic lenticule is implanted under the guidance of corneal topography in young patients with hypermetropic astigmatism residual refraction, according to the low k value. in cases where astigmatism is not present the lenticule is positioned in central position under the flap. 2. the flap of lasik is not touched or lifted but using visumax femtosecond laser we created the stromal pocket with diameter 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness set to 140 μm from corneal surface and 4 mm superior incision. hinge position flap was set at 90° angle 50° and width 4 mm, side cut angle 90°. the pocket was dissected using a blunt spatula washed with normal saline. the lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision.

Eligibility criteria:
inclusion criteria: * residual hypermetropic refraction, * low visual acuity exclusion criteria: * active anterior segment pathology, * glaucoma, * retinae detachment,
comparison of restricted versus unrestricted kinematic alignment in 1ry tka

Conditions: Osteoarthritis (OA) of the Knee; Total Knee Anthroplasty

Summary: knee osteoarthritis is a growing socioeconomic burden because of the ageing and obesity. by 2030, the majority of individuals undergoing knee arthroplasty in usa will be those younger than 65 years, with up to 1 million achieved annually. the definitive treatment for knee joint degeneration is total knee arthroplasty.

furthermore, the commonest technique is neutral mechanical alignment total knee arthroplasty. latest studies have revealed that the mechanical alignment technique repeatedly causing substantial anatomical alterations with a widespread of complex collateral ligament imbalances, which are not repairable by collateral ligament release. consequently, the total knee arthroplasty individuals walk with an abnormal gait, and they do not experience a normal knee joint. this may be one of the causes that up to 20% of total knee arthroplasty individuals are disappointed, and over 50% may have remaining symptoms. consequently, the conventional mechanical alignment technique has been recently challenged by a new alternative technique, namely unrestricted kinematic alignment proposed by howell, as a possible solution to the high dissatisfaction following total knee arthroplasty, aiming at reproducing the constitutional tibiofemoral tridimensional alignment and knee laxity. it is almost a pure bone procedure with only exceptional collateral ligament release, which has been shown to reliably position knee components. the restricted kinematic alignment protocol suggested by vendittoli has been developed as an alternative to the unrestricted kinematic alignment for patients with an outlier or atypical knee anatomy. the restricted kinematic alignment is founded on five principles: hip-knee-ankle angle should be maintained within ± 3° postoperatively; a limitation to a maximum of 5° for lateral distal femoral angle and medial proximal tibial angle may be considered; restoration of collateral ligament balance should be achieved without the gap balancing technique; native femoral anatomy preservation is suggested over tibial one to maintain knee biomechanics; resurface resection must be accomplished on the unworn side with a thickness equivalent to the width of the implant;cut fine-tuning may be sought at the worn side.

Eligibility criteria:
inclusion criteria: -patients suffered from end stage knee osteoarthritis of grade four according to kellgren-lawrence classification in at least one of the three knee compartments, who have an osteoarthritic knees of varus coronal plane alignment of the knee classification exclusion criteria: 1. any valgus malalignment of the knee joint. 2. malalignment more than 10° or less than 3° varus of knee joint. 3. ligamentous laxity of the affected knee (medial or lateral collateral ligaments) 4. any tumors or secondary neoplasia diseases 5. knee joint infection 6. severe cardiopulmonary dysfunction.

Keywords: total knee arthroplasty tka total knee replacement tkr restricted kinematic alignment rka kinematic alignment ka unrestricted kinematic alignment
postoperative in cesarean section, the women suffering from pain due to wound "incisional pain", high level laser one of most effective methods that promoting healing and decrease pain so it will effective if use in decreasing pain of cesarian section

Conditions: Cesarean Section Pain

Summary: high power laser is safe and effective methods, it's uses increasing one day after day in decreasing pain and promoting healing so its use in postoperative cesarian section will help mothers to overcome pain and return to adls faster


Eligibility criteria:
inclusion criteria: * their ages will be ranged from 20-40 years. 2. their bmi will be less than 30 kg\\m 2 3. patients with lower segment cesarean section (poursalehan et al., 2018 \& de holanda et al., 2020). exclusion criteria: * 1. patients with upper segment cesarean section. 2. diabetic patient. 3. patient with malignancy, benign tumors with the possibility to become malignant. 4. infection of the skin (poursalehan et al., 2018).

Keywords: cesarean section pain high power laser decreasing pain postoperative pain
the innate immune response and enteric nervous system in crohn's disease.

Conditions: Crohn Disease

Summary: the study aims to explore the relationships between inflammation, nerve changes, and the expression of interferon-stimulated proteins in inflamed and non-inflamed bowel areas from patients with crohn's disease. crohn's disease is a chronic inflammatory condition with complex causes and mechanisms that remain uncertain despite extensive research. methods and procedures this exploratory study utilizes tissue samples from a clinical biobank at aalborg university hospital. the samples are paraffin-embedded blocks from which tissue sections are prepared for immunohistochemical and histological staining. the study focuses on assessing the expression of interferon-stimulated proteins through optimized immunohistochemical staining methods, ensuring reproducibility via automated machines. the protein expressions are then analyzed qualitatively and semi-quantitatively and compared with structural changes in the bowel tissues.


Eligibility criteria:
inclusion criteria: * histological preparations (tissue samples) from patients with crohn's disease who have undergone bowel resection at aalborg university hospital in the period from 2012 to 2023. exclusion criteria: * if the tissue material does not include the ileocecal region. * if the pathology report does not indicate that there is tissue material from both inflamed and non-inflamed areas. * if the patient has registered a prohibition against research in the tissue utilization registry. * the selection of cases starts with the most recent (by date) and stops when 25 suitable cases are found.
therapeutic effect of quetiapine on methamphetamine-induced psychosis

Conditions: Methamphetamine-induced Psychosis

Summary: the aims of this study are to compare the antipsychotic and adverse events of quetiapine, an atypical antipsychotic drug, to haloperidol, a standard treatment for primary psychotic disorder, in individuals with map.

eighty individuals with map will be randomly assigned into two treatment groups, i.e. treatment with quetiapine and haloperidol. the quetiapine group will receive quetiapine at least 100 mg per day and the haloperidol group will receive haloperidol at least 2 mg per day orally once a day for four weeks. the doses will be increased every 5 days until no psychotic symptom is observed from the positive and negative syndrome scale. common antipsychotic adverse events will be checked and documented daily.

Eligibility criteria:
inclusion criteria: * having a psychotic episode with current use of methamphetamine * positive urine toxicology test for methamphetamine on the first day of hospitalization exclusion criteria: * using other illegal substances * having a history of primary psychotic disorders or using antipsychotic agents * having a chronic medical disease, e.g. essential hypertension, diabetes, epilepsy, stroke

Keywords: quetiapine haloperidol methamphetamine psychosis
in-office assessment of voiding function following botox injection for overactive bladder

Conditions: Overactive Bladder

Summary: the purpose of this study is to describe the rates of elevated post void residual (pvr) (defined as \>200ml) in cincinnati urogynecology associates patients following botox injection, as well as to document how many patients required treatment with clean intermittent self-catheterization (cisc).

approximately 16% of all women have symptoms of overactive bladder (oab), whereas 30% of the elderly population are affected. patients who do not respond to, or cannot tolerate, first and second line therapy with behavioral modifications and pharmacotherapy are offered additional treatment options. third line therapy involves injection of onabotulinumtoxina (botox©, allergen) into the bladder detrusor muscle. botox was approved for use for the diagnosis of oab in 2013. cincinnati urogynecology associates (cua), trihealth inc. has incorporated intravesical botox injections into the management algorithm for refractory oab, since 2014. currently, patients who fail to improve after a trial of first and second line therapy are offered treatment with botox. the standard practice is to request patients return to the office for a routine pvr measurement using straight catheterization within approximately two-four weeks following their botox injection. this is done regardless if patients are exhibiting symptoms of urinary retention. patients with an elevated pvr are treated with cisc if they are symptomatic. nevertheless, many studies suggest that patients are accurately able to self-identify symptoms of urinary retention, and treating asymptomatic urinary retention may not be necessary. the investigators aim to describe how many patients with pvr \>200ml had symptoms following intravesical injection of botox for oab.

Eligibility criteria:
inclusion criteria: * onabotulinumtoxina injections in the bladder for overactive bladder * completed a post injection appointment at which time pvr was collected (approximately 10 to 28 days following botox injection) * age \>18 * english speaking exclusion criteria: * onabotulinumtoxina injection for any other cause than overactive bladder * patients requiring self-catheterization at baseline * failure to complete a postoperative appointment within 4 weeks of botox injection
pharmacokinetics and safety of intravenous topiramate in adult patients

Conditions: Epilepsy; Migraines

Summary: the aims of this study are to determine, in adult patients on maintenance topiramate therapy, the steady-state pharmacokinetics and safety of orally and intravenously administered topiramate.

the long-term goal of this research project is to develop a more effective, safer therapy for neonatal seizures. prior to using an investigational intravenous topiramate formulation in children and neonates, the pharmacokinetics and safety of the formulation must be demonstrated in adults. the immediate aims of this study are to determine the pharmacokinetics and safety of a novel intravenous topiramate formulation. an additional aim is to determine if sex, advancing age, or genotype affects topiramate absorption, distribution, or elimination.

Eligibility criteria:
inclusion criteria: * persons taking topiramate * persons 18 years of age and older exclusion criteria: * patients who are pregnant * patients who are breast feeding * patients with significant medical problems who may not tolerate intravenous administration * patients taking medications known to affect topiramate disposition
oral 6r-bh4 for the treatment of isolated systolic hypertension and endothelial dysfunction

Conditions: Isolated Systolic Hypertension; Endothelial Dysfunction

Summary: this study is designed to assess the safety and efficacy of twice-daily oral dosing of 6r-bh4 to improve endothelial function, reduce systolic blood pressure and reduce arterial stiffness.

by comparing values measured at different timepoints, the study is expected to provide insight regarding the ability of 6r-bh4, administered along with their currently prescribed antihypertension medications, to improve endothelial function, reduce sbp, and reduce arterial stiffness in patients with ish and endothelial dysfunction

Eligibility criteria:
inclusion criteria: * no change in prescribed antihypertension medications within the previous 30 days * study staff able to visualize and measure the brachial artery diameter by high resolution vascular ultrasound required for fmd measurements * ish with the following mean seated bp: sbp \> 145 and \< 180 mmhg. diastolic blood pressure \< 90mmhg exclusion criteria: * has known hypersensitivity to 6rbh4 or its excipients * pregnant or breastfeeding at screening * use of any investigational product or investigational medical device within 30 days prior to screening * current disease or condition that would interfere with study participation or safety such as the following: heart failure, atrial fibrillation, aortic valve disease, bleeding disorders, history of repeated syncope or vertigo, severe gerd, gi ulcer, symptomatic coronary or peripheral vascular disease, arrhythmia, serious neurologic disorders including seizures, organ transplant or organ failure * hypertension secondary to other medical conditions * any severe comorbid condition that would limit life expectancy to \<6 months * current use of any nicotine containing substances * history of drug or alcohol abuse * mi, stroke or surgery within 90 days before screening visit * cabg within 6 months before the screening visit * serum creatinine \>2.0mg/dl or ast, alt, ggt levels \>2times upper limit of normal * concomitant treatment with: any drug known to inhibit folate metabolism, any phosphodiesterase-5 or -3 inhibitor * previous treatment with any formulation of bh4

Keywords: isolated systolic hypertension with endothelial dysfunction
intermittent fasting in hypertriglyceridemic overweight or obese subjects

Conditions: Hypertriglyceridemia; Overweight or Obesity

Summary: some studies have shown similar effects of intermittent fasting and continuous caloric restriction on body weight and plasma lipid profile, but there is still a wide controversy. therefore,due to limited human studies and the lack of a study on hypertriglyceridemic patients, the present study aimed to determine the effects of using low-calorie diets in comparison with continuous caloric restriction on weight loss and plasma lipid profile in obese or overweight hypertriglyceridemic patients.

a randomized clinical trial will be conducted in national nutrition and food technology research institute, tehran, iran. after the review of inclusion and exclusion criteria, a written consent form will be completed. the participants will be 90 hypertriglyceridemic patients aged between 18-60. half of the participants will be under intermittent low-calorie diet which they will have 3 alternate days in the week eating only 30% of their total energy requirement and on the other days of the week they receive a total calorie of 100% of their energy requirement , therefore there will be a total of -210% tee reduction in their received energy in the week. the other group will be under continuous calorie restriction meaning on all the days of the week they will be eating 70% of their total energy requirement resulting in a total of -210% tee reduction in their received energy in the week. both groups will receive 3 consultation sessions with a nutritionist, also to prevent any deficiency, multi-vitamin-mineral supplements will be given to both groups participants.

Eligibility criteria:
inclusion criteria: * hypertriglyceridemic : tg\>150 mg/dl * bmi\>24.9 * age 18-60 * non-smoker * haven't been under any diet at least 3 months before participating in the study * not starting any new exercise program or changing the previous exercise while in the study exclusion criteria: * chronic kidney disease stage 3-5 * consuming insulin or insulin-inducing drugs. * consuming triglycerides lowering drugs or omega 3 * a history of cholecystitis * heart arrhythmia

Keywords: intermittent fasting hypertriglyceridemia
treatment trial for post-thrombotic syndrome

Conditions: Post Thrombotic Syndrome

Summary: the purpose of this study is to determine if complex lymphedema therapy is effective in decreasing disease severity and improving quality of life in patients with post thrombotic syndrome.

post thrombotic syndrome (pts) has a spectrum of disease manifestations ranging from minor skin discoloration to severe skin changes and venous ulcerations. pain is often a prominent symptoms and pts impairs patient quality of life. prevention of pts using compression stockings has been emphasized. there is a paucity of validated, effective treatments for pts once the condition develops. while the pathophysiology of pts is incompletely understood, chronic venous hypertension and insufficiency may increase the workload of the lymphatic system and result in over-capacitance with secondary damage and eventual lymphatic insufficiency. in selected patients with pts, we have noted a symptomatic improvement in patients who receive lymphedema therapy to the limb. complex lymphedema therapy (clt) is a noninvasive treatment that includes four key components: meticulous skin care, manual lymph drainage, compression therapy, exercises and patient education for home management and continuation of the treatment. these techniques are designed to enhance lymph flow through intact cutaneous lymphatics and reduce swelling and restore function in the affected limb.

Eligibility criteria:
inclusion criteria: * age \>18 years. * diagnosis of post thrombotic syndrome. * median life expectancy of greater than 2 years. * previous history of lower extremity deep venous thrombosis. exclusion criteria: * acute venous thrombosis of the lower extremity within the last 180 days. * unable to participate in lymphedema therapy due to monetary, physical or transportation limitations. * uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * pregnant women and women in their first post-partum month.

Keywords: post thrombotic syndrome thrombosis deep vein thrombosis venous thrombosis edema stasis ulcers
treatment for presumed ocular histoplasmosis

Conditions: Ocular Histoplasmosis

Summary: the purpose of this study is to monitor safety outcomes for patients being treated with intravitreal aflibercept injections for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome.


Eligibility criteria:
inclusion criteria: * active choroidal neovascularization (cnv) secondary to presumed ocular histoplasmosis demonstrated by active leakage on fluorescein angiography with spectal domain oct evidence of subretinal or intraretinal fluid or ped. * active cnv may also be defined as demonstrating active subretinal hemorrhage. * etdrs best corrected visual acuity 20/20-20/320. * willing and able to comply with all study clinic visits and study related procedures. * willing to use and practice more than one form of contraceptives during the 13 month study for male and female. * provide signed informed consent * able to understand and complete study related questionnaires exclusion criteria: * under 18 years of age * cnv due to other causes than presumed ocular histoplasmosis * previous treatment in the study eye within 6 months prior to day 1 * more than 5 intravitreal injections of anti-vegf therapy within previous 12 months * any clinical evidence of any other ocular condition other than ocular histoplasmosis * history of allergy to fluorescein * pregnant( or planning on becoming pregnant within the next 13 months) or breast feeding women * sexually active men or women who are not willing to practice more than one form of contraceptives during the next 13 months. * anticipated or previous (within previous 3 months) systemic anti-vegf therapy

Keywords: histoplasmosis
insulin sensitivity in patients with atopic dermatitis

Conditions: Atopic Dermatitis/Eczema; Type 2 Diabetes

Summary: the incidence of atopic dermatitis and type 2 diabetes, respectively, has increased over many years. novel research shows an association between the two conditions. while this relationship at least in theory can be explained by lifestyle factors, there is reason to believe that other pathophysiological mechanisms are involved. hence, our hypothesis is that patients with atopic dermatitis are insulin resistant due to their chronic inflammatory state. insulin resistance might play an unknown part in the increased frequency of type 2 diabetes among patients with atopic dermatitis. in the present project, the investigators aim to measure insulin sensitivity by means of the 'golden standard' hyperinsulinaemic euglycaemic clamp in patients suffering from atopic dermatitis compared to a healthy control group (matched case-control study). the project is a close collaboration between the department of dermatology and allergy and center for diabetes research at gentofte hospital.


Eligibility criteria:
inclusion criteria: * moderate to severe atopic dermatitis for at least 5 years * bmi \< 30 kg/m2 * hba1c \< 42 mmol/mol exclusion criteria: * diabetes * prediabetes * first-degree relatives with diabetes * chronic inflammatory diseases other than atopic dermatitis and asthma * pregnancy * breast-feeding * daily intake of medications that are known to influence the glucose metabolism are not allowed one month before the study (e.g. asthma medicines and hormonal contraception).
targeted management intervention for african-american men with tia or stroke

Conditions: Stroke; Transient Ischemic Attack (TIA)

Summary: stroke is the leading cause of disability, third leading cause of death, and one of the most resource-intensive diseases among americans. african-americans (aa) have a stroke rate nearly double that of euro-americans (ea), and aa who experience a first-ever stroke are younger, have greater stroke disability, more post-stroke complications, and slower recovery compared to ea.


Eligibility criteria:
inclusion criteria: * self-identified aa male * between 22 and 64 years of age (\> age 21 and \< age 65). * within 6 months of discharge for stroke /tia * planned or recent home discharge * barthel index (bi) score of \> 60 * available care partner willing to participate * be able to speak and understand english exclusion criteria: * individuals who are unable or unwilling to provide written informed consent

Keywords: stroke tia african american